Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Ligon is a Physician-Scientist with expertise in neuropathology and oncology focused on improving the diagnosis and treatment of cancer. He attended medical school and received his PhD at the University of Texas-Houston Medical School and the M.D. Anderson Cancer Center. Currently he is an Associate Professor of Pathology at Harvard Medical School with joint appointments at the Dana-Farber Cancer Institute, the Broad Institute, and Brigham and Women’s Hospital (BWH). He is the Chief of Neuropathology at BWH/DFCI and the Director of the Center for Patient Derived Models (CPDM) at DFCI. His research and clinical activities have improved the scientific understanding of brain tumors. He is directly involved in the training of medical and graduate students, postdoctoral fellows, residents, and faculty. Several of the methods he has developed in his research have been implemented in the clinical pathology lab to improve patient diagnosis. He has also led efforts to train neuropathologists in the utilization of genomic tests in practice and led genomically informed clinical trials development at the local and national consortium levels.
The focus of my work is on the basic and translational investigation of brain tumors. We specifically study developmental transcription factors and their role in brain tumor formation and neural stem cell biology. Translational studies in the lab utilize genomics and pathology tools to study human tumors. Our lab has expertise in adult and pediatric gliomas and specifically our work has focused on use of human patient derived cell line and patient derived xenograft models (PDCL, PDX), mouse genetic models (GEMMs). We also have extensive collaborations around human clinical trials for brain tumors and development of biomarkers to improve outcomes of brain tumor patients.
Dana-Farber Cancer Institute450 Brookline AvenueJimmy Fund 215BBoston, MA 02215Get Directions
Brigham and Women's Hospital75 Francis StreetBoston, MA 02215Get Directions